Semaglutide Application Scope

Semaglutide is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise. It is also approved for chronic weight management in obese or overweight adults with at least one weight-related comorbidity, such as hypertension, dyslipidemia, or type 2 diabetes, providing both metabolic and cardiovascular benefits.

Semaglutide Characteristics

Ingredients: Semaglutide
Properties: White to off-white oral tablets
Packaging Specification: 3 mg, 7 mg, 14 mg × 30 tablets/box
Storage: Store below 30°C, protect from moisture and light
Expiry Date: 24 months
Executive Standard: In-house standard
Approval Number: Imported Drug Registration No. H20210032
Date of Revision: September 2022
Manufacturer: Novo Nordisk A/S (Denmark)

Guidelines for the Use of RYBELSUS

Dosage and Administration:
- Recommended Dose: Initiate at 3 mg once daily; increase to 7 mg, then 14 mg if needed
- Administration: Oral, once daily, taken with a small amount of water at least 30 minutes before first food, beverage, or other medications
- Missed Dose: Skip the missed dose and resume regular schedule; do not double dose
Adverse Reactions:
- Common Adverse Reactions: Nausea, vomiting, diarrhea, decreased appetite, abdominal pain
- Serious Adverse Reactions: Pancreatitis, severe gastrointestinal disorders, hypoglycemia (with insulin or sulfonylurea), risk of thyroid C-cell tumors
Contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- Hypersensitivity to semaglutide or excipients
- Not recommended in type 1 diabetes or for diabetic ketoacidosis
Precautions:
- Monitor blood glucose and HbA1c regularly.
- Use with caution in patients with a history of pancreatitis.
- Gradual dose escalation reduces gastrointestinal adverse effects.
- Assess renal function if severe dehydration occurs.

Semaglutide Interactions

May delay gastric emptying, affecting absorption of oral medications (e.g., levothyroxine)
Concomitant use with insulin or sulfonylureas increases the risk of hypoglycemia.
No significant pharmacokinetic interactions with metformin, warfarin, atorvastatin, or digoxin
Monitor when combined with drugs requiring precise absorption.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.